Please login to the form below

Not currently logged in
Email:
Password:

Fujifilm expands biopharma development and manufacturing business

Company invests 3.2bn yen in US and UK sites

UK SiteFujifilm Corporation is investing 3.2bn yen ($28m) to expand the biopharmaceutical manufacturing and development operations of its contract development and manufacturing business.

The funds will be shared between two sites, with 1bn yen earmarked for its Wilton Centre in Redcare, UK to install an additional facility and expand antibody production capabilities.

In addition, the company will increase its range of equipment with modern technologies including fully automated bioreactors and chromatography systems to enable “efficient monoclonal antibody production”.

Meanwhile, the remaining 2.2bn yen will be allocated to a US site in Texas, where the funds will be dedicated to the production of monoclonal antibodies at the Fujifilm Diosynth Biotechnologies site (FDB), which aims to deliver biotherapeutics and advance therapies to its customers.

More specifically, the new investment will expand Fujifilm’s existing Saturn MAb process development laboratories.

The new facilities will “ramp up operation, bolstering the company’s ability to accept orders from customers for process development and manufacturing in the field of antibodies”, the company said in a statement.

Established in 1932 as a photographic film company, Fujifilm’s diversification plans have seen it work in cGMP manufacturing for over 25 years and in 2011 it acquired Merck & Co’s biomanufacturing network to boost its protein therapeutics expertise.

Article by
Gemma Jones

14th November 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

    PMHub

    Add my company
    Wordbird

    Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

    Latest intelligence

    RWE Blog 3: Is real-world evidence the holy grail
    We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
    What do Healthcare Professionals think about the inclusion of remote selling techniques?
    Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
    Drug pricing and competition
    Strengthening business competition and reducing anti-competitive practices
    How the CMA is tackling high prices for essential drugs...

    Infographics